HighVista Strategies’s KALA BIO KALA Stock Holding History

HighVista Strategies’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-16	Closed	-$420K	–	123
2020 Q2	$420K	Buy	+16	New	+$453K	0.35%	51

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighVista Strategies's KALA Position: Q3 2020 in Review

HighVista Strategies sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 16 shares — an estimated $420K sold.

HighVista Strategies first reported a position in KALA in Q2 2020 and held it in 1 quarter. The position peaked at $420K in Q2 2020. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

HighVista Strategies reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
HighVista Strategies sold 16 KALA BIO shares in Q3 2020, an estimated $420K.
HighVista Strategies first reported a position in KALA BIO in Q2 2020 and held it in 1 quarter.
HighVista Strategies's KALA BIO position peaked at $420K in Q2 2020.
105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on HighVista Strategies's 13F filing for Q3 2020, filed 16 Nov 2020.